Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection

Julie Bruneau, MD PhD, Vincent Mallet, MD PhD, Julien Zuber, MD PhD, Cecile Alanio, PhD, Stephanie Leclerc, MD, Zakia Choucair, PhD, Kraft Anke, MD PhD, Dominique Roulot, MD, Anne-Marie Roque, MD PhD, Heiner Wedemeyer, MD PhD, Stanislas Pol, MD PhD, Patrick Hillon, MD PhD, Bruno R. Varet, MD PhD, Olivier Hermine, MD PhD

Blood (2016) 128 (22): 4898.

https://doi.org/10.1182/blood.V128.22.4898.4898

Published: 2016

Journal Articles

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

Gabriel Etienne, MD PhD, Delphine Rea, MD PhD, Joelle Guilhot, PhD, Francois Guilhot, MD, Françoise Huguet, MD, Laurence Legros, MD, Franck E. Nicolini, MD PhD, Aude Charbonnier, Agnes Guerci, MD, Bruno R. Varet, MD, Philippe Rousselot, MD PhD Professor, Francois Xavier Mahon, MD PhD

Blood (2015) 126 (23): 345.

https://doi.org/10.1182/blood.V126.23.345.345

Published: 2015

Journal Articles

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Mathilde Lamarque, MD, Véronique Leblond, MD, PhD, Bruno R. Varet, MD, Sylvain Choquet, MD, Jean Paul Vernant, MD, Richard Delarue, MD, Bertrand Godeau, MD, Olivier Hermine, MD, PhD, Marc Michel, IV

Blood (2013) 122 (21): 2193.

https://doi.org/10.1182/blood.V122.21.2193.2193

Published: 2013

Journal Articles

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

Francois-Xavier Mahon, MD, PhD, Franck E. Nicolini, MD, PhD, Marie-Pierre Noël, MD, Martine Escoffre, MD, Aude Charbonnier, MD, Delphine Rea, MD, PhD, Viviane Dubruille, Bruno R. Varet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, Gabriel Etienne, MD, PHD, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD

Blood (2013) 122 (21): 654.

https://doi.org/10.1182/blood.V122.21.654.654

Published: 2013

Journal Articles

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

Blood (2013) 122 (21): 381.

https://doi.org/10.1182/blood.V122.21.381.381

Published: 2013

Journal Articles

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Joelle Guilhot, PhD, Francois Guilhot, MD, Françoise Huguet, Franck E. Nicolini, MD, PhD, Laurence Legros, MD, PhD, Aude Charbonnier, MD, Agnès Guerci, MD, Bruno R. Varet, MD, Gabriel Etienne, MD, PHD, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2013) 122 (21): 255.

https://doi.org/10.1182/blood.V122.21.255.255

Published: 2013

Journal Articles

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, Joelle Guilhot, Francois Guilhot, Françoise Huguet, MD, Franck E. Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnès Guerci, MD, Bruno R. Varet, MD, Gabriel Etienne, MD, PhD, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2011) 118 (21): 603.

https://doi.org/10.1182/blood.V118.21.603.603

Published: 2011

Journal Articles

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

Francois-Xavier Mahon, Delphine Rea, MD, PhD, Francois Guilhot, MD, Francoise Huguet, Franck Emmanuel Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnes Guerci, Bruno R. Varet, MD, Gabriel Etienne, MD, Emilie Aton, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2009) 114 (22): 859.

https://doi.org/10.1182/blood.V114.22.859.859

Published: 2009

Journal Articles

Caspase Activated Rock-1 Allows Erythroblasts Enucleation Independently of Cytokine Signaling

Genevieve Courtois, Julie Vandekerckhove, Yunhua Chang, jean-Antoine Ribeil, Joelle Kersual, Najet Debili, William Vainchenker, Bruno R. Varet, MD, Olivier Hermine

Blood (2008) 112 (11): 2885.

https://doi.org/10.1182/blood.V112.11.2885.2885

Published: 2008

Journal Articles

Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre « Stop Imatinib » (STIM) Study

Francois-Xavier Mahon, Francoise Huguet, MD, Francois Guilhot, MD, Laurence Legros, MD, PhD, Franck E Nicolini, MD, PhD, Aude Charbonnier, Agnes Guerci, MD, Delphine Rea, MD, PhD, Bruno R. Varet, MD, Martine Gardembas, MD, Joelle Guilhot, Gabriel Etienne, Noel-Jean Milpied, MD, PhD, Emilie Aton, Josy Reiffers, Philippe Rousselot

Blood (2008) 112 (11): 187.

https://doi.org/10.1182/blood.V112.11.187.187

Published: 2008

Journal Articles

Prediction of Relapse Risk by Day 100 BCR-ABL Quantification after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia.

Marie T. Rubio, MD, PhD, Vahid Asnafi, MD, Eric Delabesse, MD, PhD, Gandhi Damaj, MD, Nathalie Dhedin, MD, Bruno R. Varet, MD, Agnes Buzyn, MD, PhD, Elizabeth A. Macintyre, MD, PhD

Blood (2005) 106 (11): 2020.

https://doi.org/10.1182/blood.V106.11.2020.2020

Published: 2005

Journal Articles

Rituximab in Anti-Mag Associated Neuropathy : A Monocentric Experience.

Richard Delarue, MD, Benedicte Deau, MD, Marie-Alexandra Alyanakian, MD, Bruno R. Varet, MD, Olivier Hermine, MD, PhD

Blood (2004) 104 (11): 4909.

https://doi.org/10.1182/blood.V104.11.4909.4909

Published: 2004

NARROW

Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

Caspase Activated Rock-1 Allows Erythroblasts Enucleation Independently of Cytokine Signaling

Is It Possible to Stop Imatinib in Patients with Chronic Myeloid Leukemia? An Update from a French Pilot Study and First Results from the Multicentre « Stop Imatinib » (STIM) Study

Prediction of Relapse Risk by Day 100 BCR-ABL Quantification after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia.

Rituximab in Anti-Mag Associated Neuropathy : A Monocentric Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only